Insulin glargine 300 U/ml
Sponsors
Sanofi
Conditions
Renal ImpairmentType 2 Diabetes Mellitus
Phase 4
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
CompletedNCT05002933
Start: 2021-05-20End: 2023-02-24Updated: 2025-09-22
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
TerminatedNCT05552859
Start: 2022-12-05End: 2023-08-04Updated: 2025-09-08